Comprehensive Assessment of Neurodegeneration and Dementia

Summary

This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.

Conditions

• Dementia
• Mild Cognitive Impairment (MCI)
• Subjective Cognitive Impairment
• Parkinson's Disease (PD)
• Lewy Body Disease(LBD)
• Mixed Dementia
• Frontotemporal Dementia (FTD)
• Alzheimer Disease (AD)
• Cognitively Unimpaired
• Subjective Cognitive Decline (SCD)

Sponsors & Collaborators

• Canadian Institutes of Health Research (CIHR)

  collaborator OTHER_GOV

• Alzheimer Society of Canada

  collaborator OTHER

• Sanofi

  collaborator INDUSTRY

• New Brunswick Health Research Foundation

  collaborator OTHER

• Saskatchewan Health Research Foundation

  collaborator OTHER

• Michael Smith Foundation for Health Research

  collaborator OTHER

• Nova Scotia Health Research Foundation

  collaborator OTHER_GOV

• Eli Lilly and Company

  collaborator INDUSTRY

• Canadian Nurses Foundation (CNF)

  collaborator OTHER

• Ontario Brain Institute

  collaborator OTHER

• Pfizer

  collaborator INDUSTRY

• Canadian Consortium on Neurodegeneration in Aging

  collaborator OTHER

• McGill University

  lead OTHER

Principal Investigators

• Michael Borrie, MD · Western University

• Natalie Philips, PhD · Concordia University, Montreal

• Jaspreet Bhangu, MB · Western University

Eligibility

Min Age

50 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2016-06-30

Primary Completion

2023-11-30

Completion

2029-12-31

Countries

• Canada

Study Locations